These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 18347007

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
    Curigliano G, Pivot X, Cortés J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A.
    Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
    [Abstract] [Full Text] [Related]

  • 3. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
    Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC, Scagliotti GV.
    J Clin Oncol; 2008 Feb 01; 26(4):650-6. PubMed ID: 18235126
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J, Kluger H, Devine L, Lee JJ, Kelly WK, Rink L, Saif MW.
    Cancer Chemother Pharmacol; 2016 Jun 01; 77(6):1193-200. PubMed ID: 27103123
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
    Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, Ohtsu A.
    Invest New Drugs; 2010 Dec 01; 28(6):866-75. PubMed ID: 19730791
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
    Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI.
    J Clin Oncol; 2006 Jan 01; 24(1):16-24. PubMed ID: 16330672
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Karachaliou N, Ziras N, Syrigos K, Tryfonidis K, Papadimitraki E, Kontopodis E, Bozionelou V, Kalykaki A, Georgoulias V, Mavroudis D.
    Cancer Chemother Pharmacol; 2012 Jul 01; 70(1):169-76. PubMed ID: 22669571
    [Abstract] [Full Text] [Related]

  • 12. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy.
    Fumoleau P, Cortés-Funes H, Taleb AB, Chan S, Campone M, Pouget JC, Tubiana-Hulin M, Slabber CF, Caroff-Paraïso I, Alberts AS, Ben Ayed F.
    Am J Clin Oncol; 2009 Aug 01; 32(4):375-80. PubMed ID: 19487917
    [Abstract] [Full Text] [Related]

  • 13. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen.
    Mina L, Krop I, Zon RT, Isakoff SJ, Schneider CJ, Yu M, Johnson C, Vaughn LG, Wang Y, Hristova-Kazmierski M, Shonukan OO, Sledge GW, Miller KD.
    Invest New Drugs; 2009 Dec 01; 27(6):565-70. PubMed ID: 19214387
    [Abstract] [Full Text] [Related]

  • 14. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.
    Atkins MB, Gravis G, Drosik K, Demkow T, Tomczak P, Wong SS, Michaelson MD, Choueiri TK, Wu B, Navale L, Warner D, Ravaud A.
    J Clin Oncol; 2015 Oct 20; 33(30):3431-8. PubMed ID: 26304872
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS.
    J Clin Oncol; 2012 Sep 10; 30(26):3234-41. PubMed ID: 22649126
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
    Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, Chouaki N, Marty M, Gamelin E, Culine S, Dieras V, Mackenzie S, Spielmann M.
    J Clin Oncol; 2002 May 15; 20(10):2551-8. PubMed ID: 12011135
    [Abstract] [Full Text] [Related]

  • 17. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
    Wang Z, Lu J, Leaw S, Hong X, Wang J, Shao Z, Hu X.
    Cancer Chemother Pharmacol; 2012 Feb 15; 69(2):515-22. PubMed ID: 21874317
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
    Ozdemir N, Aksoy S, Sendur MA, Akinci MB, Yazici O, Budakoglu B, Abali H, Oksuzoglu B, Zengin N.
    J BUON; 2013 Feb 15; 18(4):831-7. PubMed ID: 24344005
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL, Dees EC, Vukelja SJ, Amare M, Gill DP, McMahon RT, Ilegbodu D, Asmar L, O'Shaughnessy JA.
    Clin Breast Cancer; 2007 Feb 15; 7(6):465-70. PubMed ID: 17386123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.